1Department of Basic Medical Sciences, Jilin Medical University, Jilin, China
2Department of Chinese Medicine, Macau University of Science and Technology, Macau, China
3Department of Basic Medical Sciences, Yanbian Medical University, Yanji, China
4Department of Basic Medical Sciences, Beihua Medical University, Jilin, China
Corresponding authors: Ying Jin, MD Department of Basic Medical Sciences, Jilin Medical University, Jilin, Jilin Province 132013, China Tel: +86-432-64560165 • E-mail: jinying2288@163.com
Peng Peng, MD Macau University of Science and Technology, Macao 999078 Avenida Wai Long, Taipa, Macau, China Tel: +86-756-8136023 • E-mail: ppxxrice@gmail.com
Wei Zhang, MD Department of Basic Medical Sciences, Jilin Medical University, Jilin, Jilin Province 132013, China Tel: +86-432-64560352 • E-mail: jlmmczw@163.com
*These authors contributed equally to this work.
• Received: September 10, 2025 • Revised: November 10, 2025 • Accepted: November 14, 2025
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Curcumin, the main yellow pigment in turmeric, is a potent anticancer agent. However, its effect on the viability of human prostate cancer (PCa) cells and underlying mechanisms remain unclear. This study aimed to determine the effects of curcumin on the proliferation and glucose metabolism of PCa cells.
Methods
Cell viability was measured by MTS assay, and apoptosis was measured by flow cytometry. Glucose metabolism was assessed by measuring glucose intake, lactate production, and adenosine triphosphate content. Western blotting was performed to detect the expression of apoptosis-related proteins.
Results
Curcumin treatment significantly reduced the viability of two types of PCa cells. We also found that curcumin increased apoptosis and glycolysis by inhibiting the activities of phosphatidylinositol 3-kinase/protein kinase B and hypoxia-inducible factor-1α. Furthermore, curcumin reduced the expression of ETS-related gene (ERG). However, after the ERG was knocked out, the effects of curcumin treatment were attenuated.
Conclusion
This study investigated the effects of curcumin on the proliferation and apoptosis of PCa cells, which may be related to the inhibition of glycolysis, and further explored the pathway involved. The subsequent effect on ERG expression indicated that these effects may be related to this oncogene.
Prostate cancer (PCa) is the most common cancer in men and is the second leading cause of male cancer-related deaths in Western countries [1,2]. Several treatment options are available for managing localized PCa, and surgery and radiation therapy are commonly used in the management of advanced PCa.
Most patients relapse within approximately 18 to 24 months after the first androgen deprivation therapy and develop castration-resistant PCa [3,4]. Unfortunately, there is currently no efficient remedy for patients with PCa when advanced androgen signaling inhibitors, such as enzalutamide and abiraterone, fail to improve patient outcomes.
Researchers have found that natural compounds can be effective drugs for the prevention and treatment of cancer. Curcumin, a secondary metabolite of Curcuma, has a hydrophobic polyphenol structure [5-7]. It is the most abundant component in turmeric, and its natural plant metabolites are demethoxycurcumin and didemethoxycurcumin [8]. Given their shared natural pathways and ability to undergo mutual transformation, these compounds resemble each other in terms of their biological characteristics [9]. Research conducted on both animals and humans has demonstrated that 12 g of curcumin is safe to consume orally on a daily basis [10]. In addition, curcumin has a variety of biological functions, including the inhibition of angiogenesis, inhibition of inflammation, and the ability to act as an antioxidant and anticancer agent [11-13].
Metabolic alterations in tumors have gained substantial interest because they are a sign of cancer. Tumor cells exhibit prominent metabolic features such as elevated glycolysis levels, regardless of the presence of oxygen in the tumor microenvironment. The medical community acknowledges the phenomenon of aerobic glycolysis, or the Warburg effect [14,15]. Glycolysis is a major pathway that supplies energy to support the rapid proliferation of tumors. Studies have shown that focusing on glycolysis, a prominent pathway in cancer cells, may be a new way to identify novel anticancer drugs [16]. In a previous study, we showed that curcumin inhibited the growth of PCa cells, shedding light on the molecular targets associated with apoptosis.
Research has focused on utilizing curcumin as an agent to trigger the programmed death of cancer cells. However, the effects of curcumin on glucose metabolism in PCa cells are not fully understood. The ETS-related gene (ERG) transcription factor belongs to the ETS proto-oncogene family, which has a core DNA consensus sequence of GGA (A/T) [17]. Various studies have indicated the involvement of ERG in cell proliferation, differentiation, migration, and angiogenesis [18]. In the present study, we investigated the effect of curcumin on ERG expression in PCa cells and explored its mechanism of action, including changes in the metabolic phenotype and apoptosis. This study provides a better understanding of the molecular processes by which curcumin inhibits PCa cell proliferation and suggests its potential as a pioneering treatment for patients with PCa.
Methods
Ethics statements: Not applicable.
1. Cell culture and reagents
The LNCaP (RRID: CVCL_0395) and PC-3 (RRID: CVCL_0035) PCa cell lines were obtained from the Chinese Academy of Sciences (Shanghai, China). The cells were cultured in Dulbecco’s Modified Eagle Medium-Low glucose (Gibco, Grand Island, NY, USA) containing 10% fetal bovine serum (Kangyuan, Shenzhen, China), 100 µg/mL streptomycin, and 100 U/mL penicillin (Solarbio, Beijing, China). The cells were incubated at 37°C in a 5% CO2 atmosphere. Curcumin (97% purity) was purchased from Sigma-Aldrich (St. Louis, MO, USA) and dissolved in dimethyl sulfoxide. The MTS kit was purchased from Promega (Madison, WI, USA). Pyruvate kinase activity, lactic acid, ATP, and lactate dehydrogenase (LDH) assay kits were purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). Rabbit anti-human ERG, Bcl-2, Bax, cleaved caspase-3 (C-caspase-3), glucose transporter type 1 (GLUT1), pyruvate kinase M2 (PKM2), hexokinase 2 (HK2), protein kinase B (AKT), phosphorylated AKT, hypoxia-inducible factor-1 (HIF-1), and glyceraldehyde 3-phosphate dehydrogenase were purchased from ABclonal Technology (Wuhan, China).
2. Cell viability assay
Approximately 1×104 cells were plated and grown overnight in 96-well microtiter plates and treated with different concentrations of curcumin for 24 hours to evaluate the effect of curcumin on cell viability. Cell viability was analyzed by the MTS method following the manufacturer’s instructions (Promega). Optical absorbance was measured at 492 nm using a microplate reader (Apollo LB 9110; Berthold Technologies GmbH, Bad Wildbad, Germany).
3. Glucose consumption assay
The cells were treated with different concentrations of curcumin. The glucose concentration in the cell culture medium before and after curcumin treatment was determined using a glucose assay kit (Sigma-Aldrich). Glucose consumption was then calculated and normalized to the cell protein concentration.
4. Measurements of intracellular adenosine triphosphate
Intracellular ATP levels were measured using an ATP detection kit (Servicebio, Wuhan, China) following the manufacturer’s instructions. The cells were treated with different concentrations of curcumin, washed twice with ice-cold phosphate-buffered saline (PBS), and lysed in ATP lysis buffer on ice. The lysates were analyzed using a microplate reader. The ATP concentration was normalized to the protein concentration.
5. Flow cytometric evaluation of apoptosis
Cells treated with different concentrations of curcumin were harvested by centrifugation at 1,000 ×g for 3 minutes and washed with ice-cold PBS. The cell suspension (100 μL) was centrifuged at 1,000 ×g for 3 minutes. The supernatant was then discarded, and the cells were lightly suspended in 100 μL of cell culture medium and incubated with 100 μL PI staining solution. The analysis was performed within 1 hour using a BD LSRII flow cytometry system (BD Biosciences, Franklin Lakes, NJ, USA). The percentage of apoptotic cells was measured using the provided FACSDiva software (BD Biosciences).
6. Plasmids
Mammalian promoter of cytomegalovirus for hemagglutinin (HA)-tagged wild-type ERG, HA-tagged E4ERG (Δ39), and HA-tagged E5ERG (Δ99) were generated using a KOD-Plus mutagenesis kit (Toyobo, Osaka, Japan).
7. Stable cell line generation
A lentivirus transduction system was utilized to generate stable cell lines with ERG gene knockdown using the following short hairpin (sh) RNA sequences: sh-ERG#1 (5′-CCGGGCCCATCAACAGACGTTGATACTCGAGTATCAACGTCTGTTGATGGGCTTTTT-3′) and sh-ERG#2 (5′-CCGGGCTCATATCAAGGAAGCCTTACTCGAGTAAGGCTTCCTTGATATGAGCTTTTT-3′).
Lipofectamine 2000 (Thermo Fisher Scientific, Waltham, MA, USA) was used to transfect the shRNA plasmids and lentivirus package plasmids (PSPAX2 and PMD2.G) into LNCaP cells. At 48 hours after transfection, the supernatants containing viruses were collected, filtered, and used to transfect the indicated cells. Polybrene (8 mg/mL) was added during transduction to increase efficiency. At 48 hours after transduction, the culture medium was replaced with fresh medium, and puromycin (1.5 mg/mL) was administered for cell selection.
8. Western blot analysis
After treatment with curcumin, 5×105 cells were lysed in radioimmunoprecipitation assay buffer to extract total protein. The total protein content was determined with a Bio-Rad protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA), and 50 μg of protein per lane was loaded onto a polyacrylamide gel. After sodium dodecyl sulfate-polyacrylamide gel electrophoresis, the separated proteins were transferred to nitrocellulose membranes. Nonspecific binding was blocked by incubating the membranes in 5% skim milk powder in Tris-buffered saline/0.1% Tween-20 (TBST) for 120 minutes. After blocking, the blots were incubated with primary antibodies at 4°C overnight. Appropriate secondary antibodies were added and incubated for 1 hour at room temperature. After washing with TBST, a chemiluminescent liquid (MilliporeSigma, Burlington, MA, USA) was placed on the membrane, and signals were visualized with film (Kodak, Tokyo, Japan).
9. Statistical analysis
Data are presented as mean±standard deviation. Statistical analysis was performed using one-way analysis of variance for the different treatment and control groups using PASW Statistics ver. 18.0 (IBM Corp., Armonk, NY, USA). Statistical significance was set at p<0.05.
Results
1. Curcumin treatment inhibits the proliferation of prostate cancer cells
To assess the anticancer effectiveness of curcumin, the viability of LNCaP and PC-3 cells was examined using the MTS assay. The cells were treated with 0 to 80 μM curcumin for 24 hours. The results showed a significant decrease in viable LNCaP and PC-3 cells in a concentration-dependent manner. The half-maximal inhibitory concentration (IC50) values were found to be 16.9 μM and 47 μM for LNCaP and PC-3 cells, respectively (Fig. 1A, 1B). Untreated cancer cells had normal morphology and possessed cell-to-cell contacts; however, when treated with curcumin, the cells shrank and rounded up, suggesting that they underwent apoptosis (Fig. 1C).
2. Curcumin treatment induces apoptosis in prostate cancer cells
The nuclei of cells treated with or without curcumin for 24 hours were observed by Hoechst staining under a fluorescence microscope. Nuclear morphology analysis indicated that untreated cancer cells had an intact nuclear architecture, whereas the presence of small, condensed, and bright nuclei and apoptotic bodies was observed in curcumin-treated PCa cells due to the cytotoxic effect of curcumin (Fig. 2A). The percentage of Annexin V-positive cells in the two cell lines was enhanced by curcumin treatment, as indicated in the lower right panels (Fig. 2B, 2C).
3. Curcumin inhibits mitochondrial physiology in LNCaP and PC-3 cells
The fluorescent probe JC-1 is extensively used for the detection of mitochondrial membrane potential, which is related to cell biology and pertains to the movement of substances across the mitochondrial membrane and their potential-based equilibrium owing to its cationic and lipophilic properties. As the mitochondrial membrane potential fluctuates, the JC-1 dye can traverse the mitochondrial membrane effortlessly while ensuring constant equilibrium on either side. After applying curcumin to LNCaP and PC-3 cells, there was a noticeable increase in green fluorescence in the treatment group compared with that in the control group, as shown in Fig. 3, indicating a decrease in the mitochondrial membrane potential.
4. Curcumin induces apoptosis via the intrinsic pathway
To confirm this, the expression levels of key factors involved in programmed cell death were assessed in both cell lines. As shown in Fig. 4, various doses of curcumin reduced the protein levels of Bcl-2 in both cell lines compared with the control group. In addition, curcumin increased the protein levels of Bax and C-caspase-3. This suggests that curcumin not only reduces proliferation but also induces apoptosis in the two cell lines.
5. Effect of curcumin on metabolism in prostate cancer cells
After curcumin treatment for 24 hours, glucose uptake was measured in both cell types. The results showed that glucose uptake was reduced in both cell lines following curcumin treatment (Fig. 5A). The main products of aerobic glycolysis are lactic acid and ATP. Thus, ATP and lactate levels were measured to investigate whether the inhibition of glycolysis was related to curcumin treatment. The results showed that intracellular ATP and extracellular lactic acid levels were lower in both cell lines after being treated with curcumin (20, 40 μM) than in the control group (Fig. 5B, 5C).
6. Effect of curcumin on proteins related to energy metabolism
After the addition of different concentrations of curcumin to the two cell lines for 24 hours, western blotting showed that curcumin reduced the expression of GLUT1, PKM2, and HK2 (Fig. 6A), suggesting that curcumin could inhibit the glycolytic process in both cell lines. Further exploration of this pathway revealed that curcumin treatment reduced AKT phosphorylation (Fig. 6C). HIF-1α mediates cellular metabolic transformation and is regulated by the PI3K/AKT pathway. As shown in Fig. 6C, curcumin inhibited HIF-1α expression in both cell lines.
7. Curcumin induces degradation of full-length and N-terminally truncated ERGs
To determine how curcumin inhibits ERG expression, we first evaluated the baseline expression of ERG in both cell lines. The results showed that the ERG level was greater in LNCaP cells than in PC-3 cells (Fig. 7A). We subsequently treated LNCaP cells with curcumin and observed that ERG expression was inhibited in a concentration-dependent manner (Fig. 7B). Next, we examined the effect of curcumin on the expression of wild-type and N-terminal-truncated ERG E4 and E5 and observed that their expression also decreased in response to curcumin treatment (Fig. 7C).
8. Knockdown of ERG can reverse the inhibitory effect of curcumin on the malignant biological behavior of prostate cancer cells
The transduction of PCa cells with shERG lentivirus was used to determine whether the inhibitory effect of curcumin on PCa cells was related to ERG. Based on the results of cell proliferation, apoptosis, and apoptosis-related protein assays, it was found that the inhibitory and proapoptotic effects of curcumin in LNCaP cells were weaker in the ERG knockdown group than in the non-knockdown group (Fig. 8).
9. Knockdown of ERG can reverse the inhibitory effect of curcumin on the energy metabolism of prostate cancer cells
We further validated the metabolic changes of curcumin treatment in PCa cells following ERG knockdown. The results showed that the curcumin-mediated effects on glucose uptake and ATP and lactate levels were reversed in the knockdown ERG group compared with those in the non-knockdown group (Fig. 9), and the results of western blotting were consistent with these findings.
Discussion
PCa is one of the most common and lethal malignancies in men worldwide [1]. Treatment strategies for PCa have progressed substantially in the past few decades [2]. Curcumin has been used to treat various chronic diseases, including inflammation, arthritis, metabolic syndrome, liver disease, obesity, neurodegeneration, and cancers [19-21]. In the present study, PCa cells were treated with various concentrations of curcumin to explore novel therapeutic strategies.
Curcumin exerts cytotoxic activity by inhibiting or blocking mitosis and cancer cell growth. The specific focus of this study was to investigate its cytotoxicity in PCa cell lines. The IC50 of curcumin in LNCaP and PC-3 cell lines was 16.9 μM and 47 μM, respectively. Our findings indicated that curcumin inhibits cell proliferation and induces changes in cell morphology.
Abnormal cell proliferation and differentiation, as well as an imbalance in apoptosis, are important causes of tumorigenesis. Several chemotherapeutic drugs inhibit cancer cell proliferation and induce apoptosis. Major morphological changes in apoptotic cells include cell contraction, cytoplasmic vacuolation, chromatin condensation, nuclear fragmentation, and formation of cell vesicles, ultimately leading to the appearance of apoptotic bodies [22-24]. Hoechst 33342 staining revealed that both curcumin-treated cell lines exhibited typical features of apoptosis. These results were confirmed by flow cytometry and mitochondrial membrane potential analyses.
The Bcl-2 family is a class of anti-apoptotic proteins primarily involved in the endogenous pathway of apoptosis. This protein family inhibits apoptosis mainly by binding to and inhibiting proapoptotic proteins such as Bax and Bak. Cytokine C and other apoptosis-related factors play key roles in the mitochondrial apoptosis pathway and can activate the caspase pathway in cancer cells. Investigation of the mechanism by which curcumin induces apoptosis revealed that PCa cells treated with curcumin for 24 hours showed significantly reduced expression of Bcl-2 and enhanced expression of Bax and C-caspase-3.
Glycolysis is the process of converting glucose to pyruvate and producing energy and is the main method for producing important metabolite precursors. Under aerobic conditions, glycolysis is still used to provide energy, which is known as the Warburg effect [25]. This function is used by cancer cells to support metabolic reprogramming due to their high energy demands and high rate of macromolecule synthesis. The Warburg effect is regulated by several glycolytic enzymes, including HK2, phosphofructokinase, PKM2, and LDH [26]. Our results suggest that curcumin treatment inhibits glucose uptake and extracellular lactate production in PCa cells. Glycolytic enzymes were downregulated in the curcumin-treated group.
In previous studies, the PI3K/AKT signaling pathway has been associated with hypoxia. However, phosphorylation of AKT can promote hypoxia-induced HIF-1α expression and promote intracellular glucose utilization and angiogenesis, which in turn promotes intracellular environmental stabilization; this can ultimately promote the growth of tumor cells [27,28]. Our results suggest that curcumin can decrease the phosphorylation of AKT and expression of HIF-1α in PCa cells.
As a member of the ETS transcription factor family, ERG is the most frequently expressed proto-oncogene in PCa [18]. The protein encoded by this gene acts as an activator or inhibitor of transcription, and plays a regulatory role in proliferation, differentiation, apoptosis, and other cellular processes [29]. ERG is one of the most highly expressed genes in PCa and influences cancer progression by regulating Frizzled-4 expression. The transmembrane serine protease 2 (TMPRSS2)-ERG gene fusion is the most common type of genetic alteration in PCa. It is mainly due to chromosomal translocation or intergenic deletion, and most TMPRSS2-ERG fusions are frequently accompanied by deletion of tumor suppressor gene (PTEN). An association between PCa and the diagnosis of PCa has been reported [30,31].
A recent study demonstrated that TMPRSS2-ERG fusion-positive PCas can be effectively targeted by peptide-mimicking inhibitors of TMPRSS2-ERG [32]. Zhang et al. [33] demonstrated that ERG is a prognostic biomarker for survival and is associated with aerobic glycolysis in cervical cancer. In the present study, curcumin was found to be more effective against LNCaP cells than against PC-3 cells, and LNCaP cells highly expressed the ERG protein. Therefore, we speculated that the cell physiology results obtained may be related to the expression of ERG. Several experiments were conducted to test this hypothesis. The results showed that curcumin downregulated the expression of full-length and truncated ERG. We then knocked down the ERG gene in LNCaP cells and treated them with curcumin. We found that the effects of curcumin on cell proliferation, apoptosis, and energy metabolism were all reversed.
The results of this study showed that curcumin inhibited the proliferation of PCa cells and induced apoptosis. The possible mechanism is that curcumin reduces glycolysis by downregulating expression of the oncogene ERG, which in turn downregulates HIF-1α protein by inhibiting the intracellular PI3K/AKT pathway. In future studies, we will focus on further understanding the role of ERG in curcumin-treated PCa cells.
Article information
Conflicts of interest
No potential conflict of interest relevant to this article was reported.
Funding
This study was supported by the Science and Technology Department of Jilin Province (YDZJ202201ZYTS196) and the Department of Education of Jilin Province (JJKH20200453KJ and JJKH20220464KJ).
Curcumin inhibits the viability of human prostate cancer cells. (A, B) Proliferation inhibition of PC-3 (A) and LNCaP (B) cells after treatment with different concentrations of curcumin for 24 hours. (C) Cell morphology, as detected by phase contrast microscopy (×400). Data are presented as the mean±standard error of the mean of three independent experiments. OD, optical density. *p<0.05, **p<0.01 compared to controls (n=4).
Fig. 2.
Curcumin induces apoptosis in prostate cancer cell lines. (A) Fluorescent curcumin induces a decrease in the mitochondrial membrane potential in human prostate cancer cell lines. (A, B) After treatment with different concentrations of curcumin for 24 hours. (C) Data are presented as the mean±standard error of the mean of three independent experiments. **p<0.01 compared to the control group (n=3).
Fig. 3.
Curcumin induces the loss of mitochondrial membrane potential in prostate cancer cell lines. (A) Mitochondrial membrane potential analysis after treatment with different concentrations of curcumin for 24 hours. (B) Data are presented as the mean±standard error of the mean of three independent experiments. **p<0.01 compared to the control group (n=4).
Fig. 4.
Effect of curcumin on the expression of apoptosis-related proteins. (A) The expression levels of proteins related to apoptosis are determined by western blotting after treatment with 20 µM and 40 µM curcumin for 24 hours. (B) Bar graphs represent the protein expression shown in A. Data are presented as the mean±standard error of the mean of three independent experiments. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; C-Caspase-3, cleaved caspase-3. *p<0.05, **p<0.01 compared to the control group (n=3).
Fig. 5.
Curcumin decreases the rate of glycolysis in prostate cancer cells. (A) After treatment with increasing concentrations of curcumin for 24 hours, the glucose content in the culture media was assessed, and glucose uptake was calculated. (B) Measurement of lactate content. (C) ATP content was detected using a bioluminescence assay. Data are presented as the mean±standard deviation (n=4). *p<0.05, **p<0.01 compared to the control group (n=4).
Fig. 6.
Curcumin induces changes in the expression of glycolysis-related proteins and in pathways associated with prostate cancer cells. (A, C) After treatment with curcumin for 24 hours, the expression of glycolysis-related proteins and pathway-related proteins is assessed via western blot analysis. (B, D) Bar graphs showing the protein expression in A and C. Data are presented as the mean±standard deviation (n=3). GLUT1, glucose transporter type 1; PKM2, pyruvate kinase M2; HK2, hexokinase 2; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; P-AKT, phosphorylated AKT; HIF-1α, hypoxia-inducible factor-1α. *p<0.05, **p<0.01 compared with the control (n=3).
Fig. 7.
Curcumin induces degradation of full-length and truncated ETS-related gene protein. (A) Expression of ERG in different prostate cancer cells. (B) The protein expression of ERG in LNCaP cells is detected by western blot after treatment with 20 μM or 40 μM curcumin for 24 hours. (C) The full-length ERG and TMPRSS2-ERG gene fusion products E4 and E5 (truncated proteins) are detected by western blot after treatment with 20 μM curcumin for 24 hours (n=3). ERG, ETS-related gene; GAPDH, glyceraldehyde-3-phosphate dehydrogenase, WT, wild type.
Fig. 8.
Short hairpin (sh) RNA of ETS-related gene (ERG) offsets the effect of curcumin on the viability and apoptosis of LNCaP cells. (A) Selection of clone #3 showing the most efficient ERG gene knockdown. (B) The viability of LNCaP cells stably transduced with empty vector (shNc) and ERG knockdown vector (shERG) after being treated with 20 µM curcumin is detected by MTS assay. (C) Apoptosis of shNC and shERG cells after being treated with 20 µM curcumin is detected by flow cytometry. (D) Early apoptosis rates from C. (E) Protein expressions of Bcl-2, Bax, and cleaved caspase-3 (C-caspase-3) in shNc and shERG cells. (F) Bar graphs represent protein expression in D. Data are presented as the mean±standard error of the mean of three independent experiments. OD, optical density. *p<0.05, **p<0.01 compared to untreated; #p<0.05, ##p<0.01 compared to shNc+20 µM (n=3).
Fig. 9.
Short hairpin (sh) RNA of ETS-related gene (ERG) offsets the effect of curcumin on energy metabolism in LNCaP cells. (A) shERG reverses the effect of curcumin on the rate of glycolysis in prostate cancer cells. (B, D) shERG reverses the effect of curcumin on glycolysis-related proteins and in pathways associated with prostate cancer cells. (C, E) Bar graphs showing the protein expression in B and D. Data are presented as the mean±standard error of the mean of three independent experiments. GLUT1, glucose transporter type 1; PKM2, pyruvate kinase M2; HK2, hexokinase 2; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; p-AKT, phosphorylated AKT; HIF-1α, hypoxia-inducible factor-1α. *p<0.05, **p<0.01 compared to untreated; #p<0.05, ##p<0.01compared to shNc+20 µM (n=3).
References
1. Baade PD, Youlden DR, Krnjacki LJ. International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res 2009;53:171–84.ArticlePubMedPDF
2. Swanson MG, Keshari KR, Tabatabai ZL, Simko JP, Shinohara K, Carroll PR, et al. Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy. Magn Reson Med 2008;60:33–40.ArticlePubMedPMC
3. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147–54.ArticlePubMed
4. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995–2005.ArticlePubMedPMC
5. Mishra A, Das BC. Curcumin as an anti-human papillomavirus and anti-cancer compound. Future Oncol 2015;11:2487–90.ArticlePubMed
6. Feng T, Wei Y, Lee RJ, Zhao L. Liposomal curcumin and its application in cancer. Int J Nanomedicine 2017;12:6027–44.ArticlePubMedPMCPDF
7. Meng B, Li J, Cao H. Antioxidant and antiinflammatory activities of curcumin on diabetes mellitus and its complications. Curr Pharm Des 2013;19:2101–13.ArticlePubMed
8. Rainey-Smith SR, Brown BM, Sohrabi HR, Shah T, Goozee KG, Gupta VB, et al. Curcumin and cognition: a randomised, placebo-controlled, double-blind study of community-dwelling older adults. Br J Nutr 2016;115:2106–13.ArticlePubMed
9. Wang YJ, Pan MH, Cheng AL, Lin LI, Ho YS, Hsieh CY, et al. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal 1997;15:1867–76.ArticlePubMed
10. Catanzaro M, Corsini E, Rosini M, Racchi M, Lanni C. Immunomodulators inspired by nature: a review on curcumin and echinacea. Molecules 2018;23:2778.ArticlePubMedPMC
11. Divya CS, Pillai MR. Antitumor action of curcumin in human papillomavirus associated cells involves downregulation of viral oncogenes, prevention of NFkB and AP-1 translocation, and modulation of apoptosis. Mol Carcinog 2006;45:320–32.ArticlePubMed
12. Maher DM, Bell MC, O'Donnell EA, Gupta BK, Jaggi M, Chauhan SC. Curcumin suppresses human papillomavirus oncoproteins, restores p53, Rb, and PTPN13 proteins and inhibits benzo[a]pyrene-induced upregulation of HPV E7. Mol Carcinog 2011;50:47–57.ArticlePubMedPDF
13. Gopi S, Jacob J, Varma K, Jude S, Amalraj A, Arundhathy CA, et al. Comparative oral absorption of curcumin in a natural turmeric matrix with two other curcumin formulations: an open-label parallel-arm study. Phytother Res 2017;31:1883–91.ArticlePubMedPDF
14. Lu J, Chen M, Gao S, Yuan J, Zhu Z, Zou X. Ly294002 inhibits the Warburg effect in gastric cancer cells by downregulating pyruvate kinase M2. Oncol Lett 2018;15:4358–64.ArticlePubMedPMC
15. Lu W, Hu Y, Chen G, Chen Z, Zhang H, Wang F, et al. Novel role of NOX in supporting aerobic glycolysis in cancer cells with mitochondrial dysfunction and as a potential target for cancer therapy. PLoS Biol 2012;10:e1001326. ArticlePubMedPMC
16. Vaz CV, Marques R, Alves MG, Oliveira PF, Cavaco JE, Maia CJ, et al. Androgens enhance the glycolytic metabolism and lactate export in prostate cancer cells by modulating the expression of GLUT1, GLUT3, PFK, LDH and MCT4 genes. J Cancer Res Clin Oncol 2016;142:5–16.ArticlePubMedPMCPDF
17. Hollenhorst PC, McIntosh LP, Graves BJ. Genomic and biochemical insights into the specificity of ETS transcription factors. Annu Rev Biochem 2011;80:437–71.ArticlePubMedPMC
19. Ming T, Tao Q, Tang S, Zhao H, Yang H, Liu M, et al. Curcumin: an epigenetic regulator and its application in cancer. Biomed Pharmacother 2022;156:113956.ArticlePubMed
20. Dei Cas M, Ghidoni R. Dietary curcumin: correlation between bioavailability and health potential. Nutrients 2019;11:2147.ArticlePubMedPMC
21. Priyadarsini KI. The chemistry of curcumin: from extraction to therapeutic agent. Molecules 2014;19:20091–112.ArticlePubMedPMC
22. Ravichandran KS. Find-me and eat-me signals in apoptotic cell clearance: progress and conundrums. J Exp Med 2010;207:1807–17.ArticlePubMedPMCPDF
23. Fond AM, Ravichandran KS. Clearance of dying cells by phagocytes: mechanisms and implications for disease pathogenesis. Adv Exp Med Biol 2016;930:25–49.ArticlePubMedPMC
24. Kourtzelis I, Hajishengallis G, Chavakis T. Phagocytosis of apoptotic cells in resolution of inflammation. Front Immunol 2020;11:553.ArticlePubMedPMC
25. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell 2008;134:703–7.ArticlePubMed
26. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008;452:230–3.ArticlePubMedPDF
27. Wang H, Zhang C, Xu L, Zang K, Ning Z, Jiang F, et al. Bufalin suppresses hepatocellular carcinoma invasion and metastasis by targeting HIF-1α via the PI3K/AKT/mTOR pathway. Oncotarget 2016;7:20193–208.ArticlePubMedPMC
28. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005;4:988–1004.ArticlePubMedPDF
29. Adamo P, Ladomery MR. The oncogene ERG: a key factor in prostate cancer. Oncogene 2016;35:403–14.ArticlePubMedPDF
30. Cai C, Wang H, Xu Y, Chen S, Balk SP. Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. Cancer Res 2009;69:6027–32.ArticlePubMedPMCPDF
31. Brandi F, Grupp K, Hube-Magg C, Kluth M, Lang D, Minner S, et al. High concordance of TMPRSS-ERG fusion between primary prostate cancer and its lymph node metastases. Oncol Lett 2018;16:6238–44.ArticlePubMedPMC
32. Delliaux C, Tian TV, Bouchet M, Fradet A, Vanpouille N, Flourens A, et al. Tmprss2:Erg gene fusion expression regulates bone markers and enhances the osteoblastic phenotype of prostate cancer bone metastases. Cancer Lett 2018;438:32–43.ArticlePubMed
33. Zhang Z, Chen F, Li S, Guo H, Xi H, Deng J, et al. Erg the modulates Warburg effect and tumor progression in cervical cancer. Biochem Biophys Res Commun 2020;522:191–7.ArticlePubMed
Figure & Data
References
Citations
Citations to this article as recorded by
Nutraceuticals in Uro-Oncology: A Structured Expert Review and Precision-Oriented Framework Fusun Erten, Ecem Kalemoglu, Omer Kucuk, Kazim Sahin Nutrients.2026; 18(15): 2411. CrossRef
ETS-related gene as a key factor in curcumin inhibition of glucose metabolism in prostate cancer cells: an in vitro experimental study
Fig. 1. Curcumin inhibits the viability of human prostate cancer cells. (A, B) Proliferation inhibition of PC-3 (A) and LNCaP (B) cells after treatment with different concentrations of curcumin for 24 hours. (C) Cell morphology, as detected by phase contrast microscopy (×400). Data are presented as the mean±standard error of the mean of three independent experiments. OD, optical density. *p<0.05, **p<0.01 compared to controls (n=4).
Fig. 2. Curcumin induces apoptosis in prostate cancer cell lines. (A) Fluorescent curcumin induces a decrease in the mitochondrial membrane potential in human prostate cancer cell lines. (A, B) After treatment with different concentrations of curcumin for 24 hours. (C) Data are presented as the mean±standard error of the mean of three independent experiments. **p<0.01 compared to the control group (n=3).
Fig. 3. Curcumin induces the loss of mitochondrial membrane potential in prostate cancer cell lines. (A) Mitochondrial membrane potential analysis after treatment with different concentrations of curcumin for 24 hours. (B) Data are presented as the mean±standard error of the mean of three independent experiments. **p<0.01 compared to the control group (n=4).
Fig. 4. Effect of curcumin on the expression of apoptosis-related proteins. (A) The expression levels of proteins related to apoptosis are determined by western blotting after treatment with 20 µM and 40 µM curcumin for 24 hours. (B) Bar graphs represent the protein expression shown in A. Data are presented as the mean±standard error of the mean of three independent experiments. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; C-Caspase-3, cleaved caspase-3. *p<0.05, **p<0.01 compared to the control group (n=3).
Fig. 5. Curcumin decreases the rate of glycolysis in prostate cancer cells. (A) After treatment with increasing concentrations of curcumin for 24 hours, the glucose content in the culture media was assessed, and glucose uptake was calculated. (B) Measurement of lactate content. (C) ATP content was detected using a bioluminescence assay. Data are presented as the mean±standard deviation (n=4). *p<0.05, **p<0.01 compared to the control group (n=4).
Fig. 6. Curcumin induces changes in the expression of glycolysis-related proteins and in pathways associated with prostate cancer cells. (A, C) After treatment with curcumin for 24 hours, the expression of glycolysis-related proteins and pathway-related proteins is assessed via western blot analysis. (B, D) Bar graphs showing the protein expression in A and C. Data are presented as the mean±standard deviation (n=3). GLUT1, glucose transporter type 1; PKM2, pyruvate kinase M2; HK2, hexokinase 2; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; P-AKT, phosphorylated AKT; HIF-1α, hypoxia-inducible factor-1α. *p<0.05, **p<0.01 compared with the control (n=3).
Fig. 7. Curcumin induces degradation of full-length and truncated ETS-related gene protein. (A) Expression of ERG in different prostate cancer cells. (B) The protein expression of ERG in LNCaP cells is detected by western blot after treatment with 20 μM or 40 μM curcumin for 24 hours. (C) The full-length ERG and TMPRSS2-ERG gene fusion products E4 and E5 (truncated proteins) are detected by western blot after treatment with 20 μM curcumin for 24 hours (n=3). ERG, ETS-related gene; GAPDH, glyceraldehyde-3-phosphate dehydrogenase, WT, wild type.
Fig. 8. Short hairpin (sh) RNA of ETS-related gene (ERG) offsets the effect of curcumin on the viability and apoptosis of LNCaP cells. (A) Selection of clone #3 showing the most efficient ERG gene knockdown. (B) The viability of LNCaP cells stably transduced with empty vector (shNc) and ERG knockdown vector (shERG) after being treated with 20 µM curcumin is detected by MTS assay. (C) Apoptosis of shNC and shERG cells after being treated with 20 µM curcumin is detected by flow cytometry. (D) Early apoptosis rates from C. (E) Protein expressions of Bcl-2, Bax, and cleaved caspase-3 (C-caspase-3) in shNc and shERG cells. (F) Bar graphs represent protein expression in D. Data are presented as the mean±standard error of the mean of three independent experiments. OD, optical density. *p<0.05, **p<0.01 compared to untreated; #p<0.05, ##p<0.01 compared to shNc+20 µM (n=3).
Fig. 9. Short hairpin (sh) RNA of ETS-related gene (ERG) offsets the effect of curcumin on energy metabolism in LNCaP cells. (A) shERG reverses the effect of curcumin on the rate of glycolysis in prostate cancer cells. (B, D) shERG reverses the effect of curcumin on glycolysis-related proteins and in pathways associated with prostate cancer cells. (C, E) Bar graphs showing the protein expression in B and D. Data are presented as the mean±standard error of the mean of three independent experiments. GLUT1, glucose transporter type 1; PKM2, pyruvate kinase M2; HK2, hexokinase 2; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; p-AKT, phosphorylated AKT; HIF-1α, hypoxia-inducible factor-1α. *p<0.05, **p<0.01 compared to untreated; #p<0.05, ##p<0.01compared to shNc+20 µM (n=3).
Fig. 1.
Fig. 2.
Fig. 3.
Fig. 4.
Fig. 5.
Fig. 6.
Fig. 7.
Fig. 8.
Fig. 9.
ETS-related gene as a key factor in curcumin inhibition of glucose metabolism in prostate cancer cells: an in vitro experimental study